40-60% of embryos obtained by in vitro fertilization have chromosomal abnormalities, and as the pregnant woman gets older, the risk of embryo chromosomal abnormalities is higher and the probability of miscarriage is greater. During the IVF process, 24h-PGTA can complete embryo screening within 24 hours, significantly reducing the probability of embryo chromosomal abnormalities, thereby reducing the probability of miscarriage and fetal chromosomal abnormalities. Statistics found that after the pre-implantation chromosome abnormality test of the population receiving assisted reproduction treatment, the implantation rate and pregnancy rate increased, and the abortion rate decreased significantly.

Yikon Genomics uses ChromInst^® single-cell whole-genome amplification technology, combined with next-generation sequencing, to complete the aneuploidy screening of 23 pairs of chromosomes of embryos within 24 hours, and accurately analyze the copy number abnormalities of chromosomes and large fragments. Comprehensive consideration of embryo morphology and chromosome conditions to implant preferred embryos can increase the pregnancy rate of IVF and the birth rate of healthy babies.